Valo Health Receives $110 Million in Funding From Koch Disruptive Technologies to Close Series B

Valo’s CEO To Provide Insights On Programs And Opal Platform At Barclays

BOSTON, MA (March 9, 2021) — Valo Health LLC (Valo), a tech­nol­o­gy com­pa­ny trans­form­ing the drug dis­cov­ery and devel­op­ment process and seek­ing to accel­er­ate the cre­ation of life-chang­ing drugs, today announced the final clos­ing of its Series B at $300 mil­lion, includ­ing a $110 mil­lion invest­ment from Koch Dis­rup­tive Tech­nolo­gies (KDT). This brings the over­all fund­ing of Valo to over $450 million.

With this invest­ment Valo will con­tin­ue to scale its Opal Com­pu­ta­tion­al Plat­formTM, the first-of-its-kind ful­ly inte­grat­ed end-to-end plat­form that com­bines machine learn­ing-dri­ven com­pu­ta­tion­al capa­bil­i­ties and patient data to devel­op first-in-class and best-in-class ther­a­peu­tic pro­grams across major dis­ease areas.

We see Valo’s strat­e­gy and approach to trans­form­ing drug dis­cov­ery and devel­op­ment as high­ly dis­rup­tive to the indus­try. Their machine learn­ing and data-cen­tric tech­nol­o­gy solu­tions will bring sig­nif­i­cant val­ue to patients and health­care prac­ti­tion­ers look­ing for more effi­cient and enhanced treat­ment options,” said Chase Koch, Pres­i­dent of Koch Dis­rup­tive Tech­nolo­gies. The medtech and health­care mar­kets are cur­rent­ly under­go­ing dra­mat­ic change and accel­er­at­ed trans­for­ma­tion, and our invest­ment in Valo is a tes­ta­ment not only to our belief in their mis­sion but to the impor­tance of this indus­try in general.”

We are reimag­in­ing the process of dis­cov­er­ing and devel­op­ing life-chang­ing drugs in poten­tial­ly half the time, at half the cost, and with few­er fail­ures, and we are proud that KDT rec­og­nizes our par­a­digm-chang­ing work,” said David Berry, Valo founder and CEO. This invest­ment and their part­ner­ship will help us fur­ther scale and accel­er­ate our goals and the Opal platform.”

The pro­ceeds from the Series B will sup­port the con­tin­ued dis­cov­ery and devel­op­ment of ther­a­peu­tic pro­grams, fur­ther build-out the Opal Com­pu­ta­tion­al Plat­formTM, work­ing cap­i­tal, and oth­er gen­er­al pur­pos­es. Using Opal, Valo sci­en­tists have been able to iden­ti­fy pre­vi­ous­ly unsus­pect­ed asso­ci­a­tions between genet­ic mark­ers and dis­ease, which iden­ti­fy the spe­cif­ic changes in gene activ­i­ty with an ini­tial focus on oncol­o­gy, neu­rode­gen­er­a­tive, and car­dio­vas­cu­lar diseases.

David Berry will dis­cuss Valo’s approach and pro­vide insights into sev­er­al pre­clin­i­cal pro­grams and the Opal plat­form at the Bar­clays Glob­al Health­care Con­fer­ence at 8 a.m. EST on March 9, 2021. Fol­low­ing the event, a replay of the Bar­clays web­cast will be avail­able on the Valo LinkedIn page.

About Valo

Valo Health, LLC (Valo) is a tech­nol­o­gy com­pa­ny that is using human-cen­tric data and machine learn­ing com­pu­ta­tion to trans­form the drug dis­cov­ery and devel­op­ment process. As a dig­i­tal­ly native com­pa­ny, Valo is the first to ful­ly inte­grate human-cen­tric data across the entire drug devel­op­ment life­cy­cle into a sin­gle uni­fied archi­tec­ture, there­by accel­er­at­ing the dis­cov­ery and devel­op­ment of life-chang­ing drugs while simul­ta­ne­ous­ly reduc­ing the cost, time, and fail­ure rate. The com­pa­ny’s Opal Com­pu­ta­tion­al Plat­formTM, a ful­ly inte­grat­ed, com­pu­ta­tion­al, end-to-end drug devel­op­ment plat­form, offers a unique approach to ther­a­peu­tic devel­op­ment that enables Valo to advance a robust pipeline of can­di­dates across car­dio­vas­cu­lar dis­ease, oncol­o­gy, and neu­rode­gen­er­a­tion. Found­ed by Flag­ship Pio­neer­ing and head­quar­tered in Boston, MA, Valo has offices in Lex­ing­ton, MA, San Fran­cis­co, CA, Prince­ton, NJ, and in Bran­ford, CT. To learn more, vis­it www​.val​o​health​.com.

About Koch Dis­rup­tive Technologies

Koch Dis­rup­tive Tech­nolo­gies (KDT) is a unique invest­ment firm, focused on empow­er­ing founders to cre­ate a could-be world. KDT pro­vides a flex­i­ble, mul­ti-stage invest­ment approach which includes both tra­di­tion­al ven­ture and growth stages. We work with prin­ci­pled entre­pre­neurs who are build­ing trans­for­ma­tive com­pa­nies, dis­rupt­ing the sta­tus quo, and cre­at­ing new plat­forms. KDT is a sub­sidiary of Koch Indus­tries, one of the largest pri­vate­ly held com­pa­nies in the world with $110 bil­lion in rev­enue and oper­at­ing in more than 70 coun­tries. KDT helps its part­ners unlock their full poten­tial by bring­ing Koch’s capa­bil­i­ties and net­work to them, struc­tur­ing unique cap­i­tal solu­tions, and embrac­ing a long-term, mutu­al ben­e­fit mind­set. For more infor­ma­tion, vis­it www​.kochdis​rupt​.com.

Con­tacts:

Media Con­tact:

Jen­nifer Han­ley
jhanley@​valohealth.​com

Investors:

Graeme Bell
gbell@​valohealth.​com

Other
Press